BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Colorectal Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Colorectal Cancer\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885385-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06885385)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Phase 2 S
 tudy Evaluating the Safety and Efficacy of JS207 With or Without JS015 in 
 Combination With Chemotherapy in Patients With Colorectal Cancer\nEstimate
 d primary completion: 27 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06885385
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05093907-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05093907)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study t
 o Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine
  in Patients with Metastatic Colorectal Cancer\nEstimated primary completi
 on: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05093907
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736731-2310@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:A2B530: Phase 1/2 readout est. (NCT05736731)
DESCRIPTION:A2B530\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B530\, a Logic-gated CAR T\, in
  Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Ex
 pression\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/a2b530#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05736731
URL:https://assetmemo.bio/drug/a2b530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700656-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05700656)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Galuniser
 tib Combined With Capecitabine in Advanced CRC With PM\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05700656
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784688-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05784688)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of
  TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05784688
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107413-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06107413)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study to Ass
 ess Adverse Events and Change in Disease Activity in Previously Treated Ad
 ult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met
 astatic Colorectal Cancer in Combination With IV Fluorouracil\, Folinic Ac
 id\, and Bevacizumab\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06107413
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512674-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07512674)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Modified Sho
 rt-Course Radiotherapy Combined With Immunochemotherapy and Targeted Thera
 py as First-Line Treatment for MSS Metastatic Colorectal Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07512674
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107413-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06107413)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  Study to Assess Adverse Events and Change in Disease Activity in Previous
 ly Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unr
 esectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil
 \, Folinic Acid\, and Bevacizumab\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-a
 dizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06107413
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233850-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07233850)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II C
 linical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gast
 rointestinal Cancers\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07233850
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229872-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0722987
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Comb
 ined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metasta
 tic Colorectal Cancer That Has Failed Second-line or Above Treatment\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07229872
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04912765-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04912765)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoanti
 gen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From 
 CRC\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04912765
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607458-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06607458)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Evaluation o
 f the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directl
 y Into the Liver Followed by Treatment w/Approved Cancer Treatment or Appr
 oved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/
 Liver Dominant Disease\nEstimated primary completion: December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06607458
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06300463-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06300463)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Platform St
 udy of Immunotherapy Combinations in Colorectal Cancer Liver Metastases\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06300463
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843188-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05843188)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Hyd
 roxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colore
 ctal Cancer\nEstimated primary completion: 24 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05843188
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05954429-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0595442
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Study to Explore the Third-line Treatment of Fruquintinib Comb
 ined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal 
 Cancer: a Single-center\, Phase 2 Study\nEstimated primary completion: 28 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqui
 ntinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05954429
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356597-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0635659
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Tislelizumab With Fruquintinib\, Metronidazole\, in Mismatch Rep
 air-proficient or Microsatellite Stability\, Advanced Colorectal Cancer: a
  Multicenter\, Single Arm\, Clinical Trial\nEstimated primary completion: 
 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fru
 quintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06356597
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007767-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07007767)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Exploring Si
 ntilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cance
 r (After 2+ Prior Therapies）\nEstimated primary completion: 30 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0700776
 7
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321081-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06321081)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: ICE
  Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rech
 allenge Regimen in mCRC\nEstimated primary completion: 30 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06321081
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05706779-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05706779)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Encorafenib 
 Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Loc
 alised Colon or Upper Rectum Cancer\nEstimated primary completion: 30 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafeni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 706779
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Combination 
 With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Me
 tastatic Colorectal Cancer\nEstimated primary completion: 30 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Combination
  With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant M
 etastatic Colorectal Cancer\nEstimated primary completion: 30 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007728-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07007728)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Iparomlimab/
 Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy fo
 r Colorectal Cancer Liver Metastasis\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7007728
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05747716-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0574771
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Th
 ird-line Treatment in mCRC\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05747716
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05959356-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05959356)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Cet
 uximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRA
 F Wild-type\, MSS\, Unresectable Left-side Metastatic Colorectal Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05959356
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257653-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07257653)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: The
  Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without I
 mmune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type
  Unresectable Metastatic Colorectal Cancer\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cet
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07257653
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401294-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03401294)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Conversion F
 rom Unresectable To Resectable Metastatic Colorectal Cancer.\nEstimated pr
 imary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03401294
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727163-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05727163)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFOX Via H
 AI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic
  FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat
 ed CRLM Patients\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05727163
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257653-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0725765
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With
  or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/B
 RAF Wild Type Unresectable Metastatic Colorectal Cancer\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07257653
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280495-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06280495)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Neoadjuvan
 t Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT\, 
 pMMR/MSS CRC Patients\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06280495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226857-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06226857)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: Oth
 er Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided R
 AS-wild Type Metastatic Colorectal Cancer\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06226857
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03303495-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT03303495)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of 2
 nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03303495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03104439-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03104439)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Nivolumab and 
 Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancre
 atic Cancer\nEstimated primary completion: January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03104439
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03104439-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03104439)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Nivolumab and
  Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancr
 eatic Cancer\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03104439
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011576-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0701157
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment fo
 r Participants With Metastatic Colorectal Cancer (FRUITFUL)\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07011576
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06951503)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: A
 K112 and Chemotherapy in First-line Metastatic Colorectal Cancer\nEstimate
 d primary completion: 13 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06951503
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835179-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06835179)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: SBRT Combine
 d With CAPEOX\, Bevacizumab\, and PD-1 Inhibitor for the Treatment of RAS-
 Mutant\, MSS-Type\, Unresectable Metastatic Colorectal Cancer.\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06835179
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229846-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07229846)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Single-arm
 \, Single-center\, Phase II Clinical Study of Aipalolitovorelizumab (QL170
 6) Combined With Bevacizumab and Standard Chemotherapy as First-line Treat
 ment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07229846
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229846-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07229846)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Single-ar
 m\, Single-center\, Phase II Clinical Study of Aipalolitovorelizumab (QL17
 06) Combined With Bevacizumab and Standard Chemotherapy as First-line Trea
 tment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation\n
 Estimated primary completion: February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07229846
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801665-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06801665)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FMT+ QL1706+
 Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorecta
 l Cancer With Liver Metastasis\nEstimated primary completion: 1 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06801665
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gli
 oblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06047379
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Regorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: Safety and
  Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glioblastoma
  IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0604
 7379
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Clinical Trial of TB511 in Advanced Solid Tumors\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06400160
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study o
 f a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpo
 int Blockade for Patients With Metastatic Colorectal Cancer\nEstimated pri
 mary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of
  a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoi
 nt Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Ipilimumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of 
 a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoin
 t Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05141721
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510932-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0751093
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib In Patients With Metastatic Colorectal Cancer Refra
 ctory to Standard Chemotherapies in South Korea Patients (FIRST-K)\nEstima
 ted primary completion: 1 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07510932
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558773-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06558773)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: GSL Syntheta
 se Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previo
 usly Treated pMMR/MSS CRC.\nEstimated primary completion: 1 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06558773
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255379-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270321
DTEND;VALUE=DATE:20270322
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0625537
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil i
 n Patients With Metastatic Colorectal Cancer\nEstimated primary completion
 : 21 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruq
 uintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06255379
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701476-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04701476)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 ATE and Pembrolizumab (MK3475) in mCRC and NSCLC\nEstimated primary comple
 tion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04701476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701476-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Regorafenib: Phase 2 readout est. (NCT04701476)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: TATE and Pem
 brolizumab (MK3475) in mCRC and NSCLC\nEstimated primary completion: 31 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047
 01476
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794971-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Regorafenib: Phase 3 readout est. (NCT05794971)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Regorafenib 
 Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Me
 tastases\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05794971
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (K
 RAS G12C)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255664-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07255664)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A FIH\, 
 Phase I/IIa\, Trial Assessing Feasibility of Administrations of TIL-based 
 Immunotherapy in Patients With Metastatic CRC and PC\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07255664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118724-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05118724)
DESCRIPTION:Atezolizumab\, phase 2\, Colorectal Cancer.\nStudy: Atezolizuma
 b in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal
  Cancer Ineligible for Oxaliplatin\nEstimated primary completion: April 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05118724
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04730544-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04730544)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Two Combinatio
 n Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and
  / or MSI mCRC.\nEstimated primary completion: April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04730544
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04730544-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04730544)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Two Combinati
 on Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR an
 d / or MSI mCRC.\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04730544
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919264-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05919264)
DESCRIPTION:Nivolumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOG-001 in L
 ocally Advanced or Metastatic Solid Tumors\nEstimated primary completion: 
 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5919264
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919264-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05919264)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOG-001 in
  Locally Advanced or Metastatic Solid Tumors\nEstimated primary completion
 : 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05919264
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106308-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06106308)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Onv
 ansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevaciz
 umab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Li
 ne Treatment of Metastatic Colorectal Cancer in Adult Participants With a 
 KRAS or NRAS Mutation\nEstimated primary completion: 16 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06106308
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379595-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05379595)
DESCRIPTION:Amivantamab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy 
 in Participants With Advanced or Metastatic Colorectal Cancer\nEstimated p
 rimary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05379595
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930118-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06930118)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: The Aim of T
 his Study is to Assess the Efficacy and Safety of Chidamide\, Regorafenib 
 in Combination With Iparomlimab and Tuvonralimab for the Treatment of Adva
 nced Colorectal Cancer in Third-line Therapy and Subsequent Lines.\nEstima
 ted primary completion: 30 April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06930118
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930118-2286@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Chidamide: Phase 2 readout est. (NCT06930118)
DESCRIPTION:Chidamide\, phase 2\, Colorectal Cancer.\nStudy: The Aim of Thi
 s Study is to Assess the Efficacy and Safety of Chidamide\, Regorafenib in
  Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanc
 ed Colorectal Cancer in Third-line Therapy and Subsequent Lines.\nEstimate
 d primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06930118
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855849-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06855849)
DESCRIPTION:Amivantamab\, phase 2\, Colorectal Cancer.\nStudy: An Open-labe
 l\, Single-arm\, Multicenter Phase II Study to Evaluate the Efficacy of Am
 ivantamab in Combination With FOLFIRI as a Second-line Treatment in Patien
 ts With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior
  Anti-EGFR Based Treatment.\nEstimated primary completion: May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855849
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operative 
 Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (
 UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Sotorasib\, phase 2\, Colorectal Cancer.\nStudy: Pre-operative 
 Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (
 UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Amivantamab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operativ
 e Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer
  (UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Botensilimab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operati
 ve Targeted Treatments in Molecularly Selected Resectable Colorectal Cance
 r (UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411600-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06411600)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Com
 bination Therapy for BRAF-V600E Metastatic CRCm\nEstimated primary complet
 ion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06411600
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071961-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07071961)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: Regorafenib 
 (Reg) and Lorigerlimab (Lor)\, RELO Regimen\, in Treatment of High-risk Pa
 tients With Colorectal Cancer With Radiographic Occult Molecular Residual 
 Disease After End of Established Definitive Therapy [ReLOAD Trial]\nEstima
 ted primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071961
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411600-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06411600)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Combination 
 Therapy for BRAF-V600E Metastatic CRCm\nEstimated primary completion: 1 Ma
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafenib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06411
 600
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:Capecitabine\, phase 2/3\, Colorectal Cancer.\nStudy: A Phase 
 Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unrese
 ctable or Metastatic Colorectal Cancer\nEstimated primary completion: 12 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 62143
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570914-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07570914)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Hepatic Art
 erial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine a
 s Adjuvant Therapy for Colorectal Cancer Liver Metastases\nEstimated prima
 ry completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07570914
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959589-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06959589)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: The
  Efficacy and Safety of IBI351\, Cetuximab β Combined With FOLFIRI as Fir
 st-line /IBI351\, Cetuximab β as Second-line in the Treatment of KRAS G12
 C-mutated Metastatic Colorectal Cancer\nEstimated primary completion: 31 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069595
 89
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559760-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07559760)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: New
  Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer\nEstimated
  primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07559760
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559760-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07559760)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: New Second-L
 ine Combo Therapy for MSS Metastatic Colorectal Cancer\nEstimated primary 
 completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07559760
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653685-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07653685)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinical
  Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevac
 izumab in Patients With HER2-Abnormally Expressed Unresectable Locally Adv
 anced or Metastatic Colorectal Cancer.\nEstimated primary completion: June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076536
 85
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653685-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07653685)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinica
 l Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Beva
 cizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Ad
 vanced or Metastatic Colorectal Cancer.\nEstimated primary completion: Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0765
 3685
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the
  Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alon
 e for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the 
 Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone
  for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prima
 ry completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134205-2224@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Becotatug: Phase 3 readout est. (NCT07134205)
DESCRIPTION:Becotatug\, phase 3\, Colorectal Cancer.\nStudy: The Study of J
 MT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Co
 lorectal Cancer\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07134205
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627635-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05627635)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOLFOX and
  Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) 
 for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Can
 cer\nEstimated primary completion: 16 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05627635
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627635-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Botensilimab: Phase 1/2 readout est. (NCT05627635)
DESCRIPTION:Botensilimab\, phase 1/2\, Colorectal Cancer.\nStudy: FOLFOX an
 d Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX)
  for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Ca
 ncer\nEstimated primary completion: 16 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05627635
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792695-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06792695)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study of N
 ovel Study Interventions and Combinations in Participants With Colorectal 
 Cancer\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06792695
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634875-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06634875)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Isunakinra
  Alone and in Combination With Pembrolizumab in Patients With Colorectal C
 ancer (MSS)\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06634875
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150247-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07150247)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Safety and E
 fficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07150247
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150247-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07150247)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Met
 astatic Colorectal Cancer\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonral
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07150247
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591597-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07591597)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Multic
 enter\, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of 
 Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 P
 lus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal C
 ancer\nEstimated primary completion: July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07591597
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591597-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT07591
 597)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: A Multicenter\, Phase Ib/II Clinical Trial to Evaluate the Eff
 icacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruqui
 ntinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With M
 SS/pMMR Colorectal Cancer\nEstimated primary completion: July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07591597
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051785-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0705178
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome an
 d Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal C
 ancer\nEstimated primary completion: 6 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07051785
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051785-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07051785)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Fruquintini
 b vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Sec
 ond-Line Therapy for Advanced Metastatic Colorectal Cancer\nEstimated prim
 ary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07051785
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515820-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0751582
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study\nEs
 timated primary completion: 28 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07515820
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106034-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07106034)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Standard Sec
 ond-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal C
 ancer: a Single-arm Phase II Trial\nEstimated primary completion: 31 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0710603
 4
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589440-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06589440)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Phase 2 Stu
 dy of SR-8541A in Combination With Botensilimab and Balstilimab in Subject
 s With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-
 CRC)\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06589440
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614192-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06614192)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study Assessing Adverse Events and Disease Activity of Intravenously (I
 V) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Prote
 in Above Cutoff Level Above Refractory Metastatic Colorectal Cancer\nEstim
 ated primary completion: August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06614192
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07483684)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: A Clinical S
 tudy to Evaluate Injection TQB2102 for the Treatment of Patients With HER2
  IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal
 iplatin\, Irinotecan and Fluoropyrimidine-Based Drugs\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07483684
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0748368
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: A Clinical Study to Evaluate Injection TQB2102 for the Treatment
  of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed Aft
 er Treatment With Oxaliplatin\, Irinotecan and Fluoropyrimidine-Based Drug
 s\nEstimated primary completion: August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07483684
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446322-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07446322)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFIRI and 
 Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metast
 atic RAS-Mutated\, Microsatellite-Stable Colorectal Cancer\nEstimated prim
 ary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07446322
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446322-9106@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Pelareorep: Phase 2 readout est. (NCT07446322)
DESCRIPTION:Pelareorep\, phase 2\, Advanced Metastatic Colorectal Cancer.\n
 Study: FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line 
 Treatment of Metastatic RAS-Mutated\, Microsatellite-Stable Colorectal Can
 cer\nEstimated primary completion: 30 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pelareorep#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07446322
URL:https://assetmemo.bio/drug/pelareorep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353268-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0735326
 8)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard T
 hird-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Can
 cer: Safety\, Tolerability\, and Efficacy.\nEstimated primary completion: 
 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqu
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07353268
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608044-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Botensilimab: Phase 2 readout est. (NCT05608044)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of 
 Botensilimab and Balstilimab for the Treatment of Colorectal Cancer\nEstim
 ated primary completion: September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05608044
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215936-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07215936)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Dose-dense 
 Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Compa
 rison With Standered Regimen\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07215936
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123441-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07123441)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study on t
 he Efficacy and Safety of Irinotecan Liposome (II)\, 5-FU/LV in Combinatio
 n With Bevacizumab for the Treatment of Advanced Colorectal Cancer\nEstima
 ted primary completion: 1 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07123441
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819604-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07819604)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Serplulimab 
 Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Adv
 anced Colorectal Cancer\nEstimated primary completion: 1 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07819604
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788171-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06788171)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: PULSAR Combi
 ned With PD-1 Ab and Chemotherapy Plus Bev. for CRLM\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06788171
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788171-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06788171)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: PULSAR Comb
 ined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM\nEstimated primary c
 ompletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06788171
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Regorafenib: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: An Open-Labe
 l Study to Enable Continued Treatment Access for Subjects Previously Enrol
 led in Studies of Ruxolitinib\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0295594
 0
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: An Open-Label Study to Enable Continued Treatment Access for Subject
 s Previously Enrolled in Studies of Ruxolitinib\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02955940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474727-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07474727)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II S
 tudy of AMT-676 Combination Therapies in Advanced Colorectal Cancer\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07474727
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Dato-D
 Xd as Monotherapy and in Combination With Anti-cancer Agents in Patients W
 ith Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary complet
 ion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05489211
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Study of Da
 to-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patien
 ts With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary com
 pletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05489211
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407465-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07407465)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Upfront Tras
 tuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER
 -2 Positive Metastatic Colorectal Cancer.\nEstimated primary completion: 2
 0 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07407465
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407465-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07407465)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Upfront Tra
 stuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HE
 R-2 Positive Metastatic Colorectal Cancer.\nEstimated primary completion: 
 20 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07407465
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261709-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0726170
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipira
 cil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomi
 zed\, Controlled\, Open-Label\, Non-Inferiority Trial\nEstimated primary c
 ompletion: 30 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07261709
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021950-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07021950)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A
 K112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment
  of MSS/pMMR Metastatic Colorectal Cancer\nEstimated primary completion: 3
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07021950
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621159-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT07621
 159)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: A Phase Ib/II Study of HDM2017 in Combination With Standard of
  Care in Advanced Colorectal Cancer\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 621159
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978400-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06978400)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A S
 tudy of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Lin
 e of Therapy in People With Metastatic Colorectal Cancer\nEstimated primar
 y completion: 10 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06978400
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: JSKN003 Vers
 us Physician Choiced Treatment in Patients With HER2-positive and Advanced
  Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 5-Fu\, and I
 rinotecan\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07384377
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0738437
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: JSKN003 Versus Physician Choiced Treatment in Patients With HER2
 -positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxal
 iplatin\, 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07384
 377
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-9179@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Anbenitamab repodatecan\, phase 3\, Colorectal Cancer.\nStudy: 
 JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive 
 and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 
 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/anbenitamab-repodatecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 4377
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Spevatam
 ig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted The
 rapy and/or ICI\, for the Treatment of Patients With Advanced Gastrointest
 inal Cancers\, Including Gastric\, Gastroesophageal Junction\, Pancreatic 
 Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05482893
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Spevatamig
  (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Thera
 py and/or ICI\, for the Treatment of Patients With Advanced Gastrointestin
 al Cancers\, Including Gastric\, Gastroesophageal Junction\, Pancreatic Du
 ctal or Biliary Tract Carcinomas (the TWINPEAK Study)\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05482893
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A P
 hase II Study of Sintilimab Combined With Ipilimumab N01\, Cetuximab and D
 abrafenib in Patients With Microsatellite-Stable\, BRAF V600E-Mutated Meta
 static Colorectal Cancer\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II St
 udy of Sintilimab Combined With Ipilimumab N01\, Cetuximab and Dabrafenib 
 in Patients With Microsatellite-Stable\, BRAF V600E-Mutated Metastatic Col
 orectal Cancer\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730489-2282@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07730489)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Colorectal Cancer.\nStudy: 
 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients Wit
 h HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Ox
 aliplatin\, Fluorouracil and Irinotecan\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07730489
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136077-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0713607
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-define
 d Minimal Residual Disease in Colorectal Cancer After Completion of Adjuva
 nt Chemotherapy\nEstimated primary completion: 1 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07136077
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622550-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0762255
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Single-arm\, Multicenter Clinical Study of Fruquintinib Combin
 ed With Serplulimab and Chemotherapy as First-line Treatment for Patients 
 With RAS/BRAF-mutated Advanced Colorectal Cance\nEstimated primary complet
 ion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fruquintinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07622550
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750094-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06750094)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Partici
 pants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previou
 sly Received Chemotherapy\nEstimated primary completion: 15 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06750094
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: E
 ncorafenib\, Cetuximab\, and Nivolumab in Treating Patients With Microsate
 llite Stable\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Can
 cer\nEstimated primary completion: 30 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Nivolumab\, phase 1/2\, Colorectal Cancer.\nStudy: Encorafenib\
 , Cetuximab\, and Nivolumab in Treating Patients With Microsatellite Stabl
 e\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer\nEstima
 ted primary completion: 30 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Encorafenib: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Encorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: Encorafeni
 b\, Cetuximab\, and Nivolumab in Treating Patients With Microsatellite Sta
 ble\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059338-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07059338)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Dua
 l EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Po
 sitive Metastatic Colorectal Cancer\nEstimated primary completion: 30 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0705
 9338
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07503756)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: JS212 Combin
 ation Therapies in Metastatic Colorectal Cancer\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07503756
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314294-2116@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bafisontamab: Phase 2 readout est. (NCT07314294)
DESCRIPTION:Bafisontamab\, phase 2\, Advanced Metastatic Colorectal Cancer.
 \nStudy: Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cance
 r Patients\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bafisontamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07314294
URL:https://assetmemo.bio/drug/bafisontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896096-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0789609
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Pa
 tients With Metastatic Colorectal Cancer After Failure of Second-line or L
 ater Treatment\nEstimated primary completion: 30 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07896096
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07503756)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: JS212 Combi
 nation Therapies in Metastatic Colorectal Cancer\nEstimated primary comple
 tion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07503756
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750041-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07750041)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07750041
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750041-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT07750041)
DESCRIPTION:Regorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07750041
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729322-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04729322)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Fecal Micr
 obiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab 
 or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD
 -1 Non-responders\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04729322
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729322-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04729322)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Fecal Microbio
 ta Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or N
 ivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 N
 on-responders\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04729322
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691632-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07691632)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Serplulimab
  Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal 
 Cancer\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07691632
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846268-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06846268)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvan
 t ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06846268
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562490-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07562490)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Randomized
  Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy
  Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07562490
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992258-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0699225
 8)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compar
 ed to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorec
 tal Cancer\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06992258
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562659-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07562659)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Randomized 
 Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy 
 in Stage I/Low-Risk Stage II Colorectal Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07562659
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253651-2271@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 3 readout est. (NCT05253651)
DESCRIPTION:Tucatinib\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 atinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in 
 First-line HER2+ Metastatic Colorectal Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05253651
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992648-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Regorafenib: Phase 3 readout est. (NCT06992648)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Trifluridine
 /Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for
  Refractory Metastatic Colorectal Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regor
 afenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06992648
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699836-1012@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Leronlimab: Phase 2 readout est. (NCT06699836)
DESCRIPTION:Leronlimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: CL
 OVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor
  Enriched Regimen\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/leronlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06699836
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699836-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06699836)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: CLOVER - C
 CR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriche
 d Regimen\nEstimated primary completion: January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06699836
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563986-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06563986)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FTD-TPI\, Be
 vacizumab\, and Radioembolization With 166Ho-microspheres in Refractory Me
 tastatic Colorectal Cancer\nEstimated primary completion: January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06563986
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05504252-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05504252)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: METIMMOX-2: Me
 tastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxali
 platin\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05504252
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941310-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07941310)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase 2 St
 udy of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal 
 Cancer\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07941310
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178717-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07178717)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to C
 haracterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V
 600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W
 ith BRAF Inhibitors-based Combinations\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 178717
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178717-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Encorafenib: Phase 2 readout est. (NCT07178717)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: A Study to C
 haracterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V
 600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W
 ith BRAF Inhibitors-based Combinations\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafeni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 178717
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07337551-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07337551)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Gossypol Ace
 tate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive\nEstimat
 ed primary completion: 1 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07337551
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888843-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06888843)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Study to Ev
 aluate the Use of Capecitabine in Monotherapy and in Combination With Oxal
 iplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced 
 Colorectal Cancer.\nEstimated primary completion: 1 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06888843
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®
 \, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in
  Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal Can
 cer\nEstimated primary completion: 15 February 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to E
 valuate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo
 ®\, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care 
 in Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal C
 ancer\nEstimated primary completion: 15 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070713-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07070713)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Efficacy and
  Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in 
 First-Line Treatment of Left-Sided mCRC\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07070713
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150403-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0715040
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruqui
 ntinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in
  Metastatic Colorectal Cancer\nEstimated primary completion: 28 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715040
 3
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070713-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07070713)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Beva
 cizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC\nEstim
 ated primary completion: 28 February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07070713
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820463-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06820463)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to E
 valuate the Adverse Events\, and Efficacy of Intravenous (IV) of Telisotuz
 umab Adizutecan in Combination With IV Oxaliplatin\, Fluorouracil\, Folini
 c Acid/Leucovorin\, Bevacizumab\, Panitumumab in Adult Participants With M
 etastatic Colorectal Cancer\nEstimated primary completion: March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06820463
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820463-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06820463)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Evaluate the Adverse Events\, and Efficacy of Intravenous (IV)
  of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin\, Fluorour
 acil\, Folinic Acid/Leucovorin\, Bevacizumab\, Panitumumab in Adult Partic
 ipants With Metastatic Colorectal Cancer\nEstimated primary completion: Ma
 rch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzum
 ab-adizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06820463
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409844-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07409844)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvan
 t Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III d
 MMR Colon Cancer\nEstimated primary completion: 1 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07409844
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642844-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280304
DTEND;VALUE=DATE:20280305
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06642844)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Bevacizumab-
 based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Tre
 atment\nEstimated primary completion: 4 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06642844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542262-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07542262)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Low-dose Immun
 otherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMM
 R Cancers\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07542262
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 llogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in 
 Advanced Solid Tumors\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2242@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:S-1\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Allogenei
 c NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced
  Solid Tumors\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Allogenei
 c NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced
  Solid Tumors\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244705-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07244705)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Adva
 nced or mCRC\nEstimated primary completion: April 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07244705
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503639-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07503639)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Umbrella Tr
 ial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07503639
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI P
 lus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR
  and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary 
 completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06733038
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI Pl
 us Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR 
 and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06733038
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130903-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280417
DTEND;VALUE=DATE:20280418
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0713090
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF
  EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal
  Cancer\nEstimated primary completion: 17 April 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07130903
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936527-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06936527)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: XS-03 in C
 ombination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metasta
 tic Colorectal Cancer Patients With RAS Mutation\nEstimated primary comple
 tion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06936527
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizu
 mab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07915921
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or C
 etuximab in Patients With RAS-mutant Metastatic Colorectal Cancer\nEstimat
 ed primary completion: 30 April 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07915921
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796763-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07796763)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: A 
 Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chem
 otherapy and Bevacizumab as First-Line Treatment in Patients With Advanced
  Colorectal Cancer Expressing HER2\nEstimated primary completion: 1 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezet
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07796763
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of T
 ucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Col
 orectal Cancer Patients\nEstimated primary completion: 31 May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228832-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07228832)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: P
 hase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patie
 nts With Metastatic Colorectal Cancer\nEstimated primary completion: 31 Ma
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07228
 832
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2286@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Chidamide: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Chidamide\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 idinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Color
 ectal Cancer Patients\nEstimated primary completion: 31 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malign
 ancies\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535632-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07535632)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: SBRT Followe
 d by PD-1 Inhibitor\, Bevacizumab and TAS-102 as Third-Line Therapy for Re
 current/Metastatic Colorectal Cancer\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075356
 32
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927049-2286@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Chidamide: Phase 2/3 readout est. (NCT07927049)
DESCRIPTION:Chidamide\, phase 2/3\, Colorectal Cancer.\nStudy: Evaluating t
 he Efficacy of Chidamide in the Treatment of Initial Unresectable Metastat
 ic Colorectal Cancer With High Expression of SULF1\nEstimated primary comp
 letion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07927049
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927075-2286@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Chidamide: Phase 2/3 readout est. (NCT07927075)
DESCRIPTION:Chidamide\, phase 2/3\, Colorectal Cancer.\nStudy: Evaluating t
 he Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With Hig
 h SULF1 Expression\nEstimated primary completion: 1 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07927075
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683403-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07683403)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: S
 avolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type M
 etastatic Colorectal Cancer\nEstimated primary completion: 30 June 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07683403
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268015-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06268015)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Botensilimab
  and Balstilimab Optimization in Colorectal Cancer\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 vacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06268015
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268015-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06268015)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Botensilima
 b and Balstilimab Optimization in Colorectal Cancer\nEstimated primary com
 pletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 otensilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06268015
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895355-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07895355)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotu
 zumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorecta
 l Cancer\nEstimated primary completion: July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07895355
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06666166-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06666166)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: SH
 R-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gas
 troesophageal Junction Adenocarcinoma and Colorectal Cancer\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06666166
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025239-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07025239)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Metastatic Colorectal 
 Cancer.\nStudy: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plu
 s Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic
  Colorectal Cancer\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07025239
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959550-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06959550)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: P
 hase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patient
 s With Previously Treated Metastatic Colorectal Cancer\nEstimated primary 
 completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06959550
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243938-2242@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:S-1: Phase 2 readout est. (NCT07243938)
DESCRIPTION:S-1\, phase 2\, Colorectal Cancer.\nStudy: Phase II Basket Tria
 l: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BA
 SKET)\nEstimated primary completion: 30 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07243938
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243938-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07243938)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Phase II Ba
 sket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNIO
 N-HER2-BASKET)\nEstimated primary completion: 30 July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07243938
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722754-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07722754)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Bev
 acizumab\, Sintilimab\, Cetuximab and Irinotecan in Refractory RAS Wild-ty
 pe Metastatic Colorectal Cancer: BOND-4 Trial\nEstimated primary completio
 n: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07722754
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722754-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07722754)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Bevacizumab\
 , Sintilimab\, Cetuximab and Irinotecan in Refractory RAS Wild-type Metast
 atic Colorectal Cancer: BOND-4 Trial\nEstimated primary completion: 31 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07722
 754
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844620-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Regorafenib: Phase 2 readout est. (NCT03844620)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: Circulating 
 Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advance
 d or Metastatic Colorectal Cancer\nEstimated primary completion: 31 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038446
 20
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134101-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07134101)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant 
 Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)\nEstimated pr
 imary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07134101
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134101-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07134101)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant
  Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)\nEstimated p
 rimary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07134101
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05854498-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05854498)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Liposomal Ir
 inotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorect
 al Cancer\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05854498
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550088-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07550088)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: BAL/BOT/age
 nT-797 in pMMR CRC With Liver Metastases\nEstimated primary completion: Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/botensi
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07550088
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02885753-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT02885753)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Systemic Oxa
 liplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinoteca
 n and an Target Therapy in First Line Treatment of Metastatic Colorectal C
 ancer Restricted to the Liver\nEstimated primary completion: September 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02885753
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440902-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06440902)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Exp
 loration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorec
 tal Cancer Based on Circulating Tumor DNA\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06440902
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239741-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05239741)
DESCRIPTION:Pembrolizumab\, phase 3\, Colorectal Cancer.\nStudy: Study of P
 embrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With St
 age IV Colorectal Cancer (MK-3475-C66)\nEstimated primary completion: 19 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05239741
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252649-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Sotorasib: Phase 3 readout est. (NCT06252649)
DESCRIPTION:Sotorasib\, phase 3\, Colorectal Cancer.\nStudy: Study of Sotor
 asib\, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-
 awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer Wi
 th KRAS p.G12C Mutation\nEstimated primary completion: 25 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06252649
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of R
 AS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors\nEstimate
 d primary completion: 30 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904130-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0790413
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Personalized Ultrafractionated Stereotactic Adaptive Radiotherap
 y Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
 \nEstimated primary completion: 1 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07904130
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724223-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0772422
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of
  RAS Wild-Type mCRC\nEstimated primary completion: 1 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07724223
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-98652
 3 Alone and in Combination With Anti-Cancer Agents in Participants With Ad
 vanced Solid Malignancies\nEstimated primary completion: 13 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912593-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07912593)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  KRAS Inhibitor in Participants With Advanced Solid Tumors\nEstimated prim
 ary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07912593
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07722494)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combi
 ned With Bevacizumab for Advanced Colorectal Cancer\nEstimated primary com
 pletion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07722494
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2254@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IBI363: Phase 3 readout est. (NCT07722494)
DESCRIPTION:IBI363\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combined W
 ith Bevacizumab for Advanced Colorectal Cancer\nEstimated primary completi
 on: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ibi363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07722494
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913360-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07913360)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: GFH
 375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Muta
 nt Refractory Metastatic Colorectal Cancer\nEstimated primary completion: 
 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07913360
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737600-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07737600)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  MRG007 Combination Therapy for Advanced Colorectal Cancer\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07737600
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737600-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07737600)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study o
 f MRG007 Combination Therapy for Advanced Colorectal Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07737600
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tum
 ors\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071844-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07071844)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: BETWEEN: Biw
 eekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia
  in mCRC Patients\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07071844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527858-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07527858)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Denik
 itug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adult
 s With Advanced Colorectal Cancer\nEstimated primary completion: December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527858
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527858-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07527858)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Den
 ikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adu
 lts With Advanced Colorectal Cancer\nEstimated primary completion: Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527
 858
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887218-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06887218)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: 5-Fluorourac
 il/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Me
 tastatic Colorectal Cancer\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06887218
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042685-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0704268
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With 
 Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic 
 Colorectal Cancer\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07042685
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662786-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06662786)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIR
 I as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-typ
 e Unresectable or Metastatic Left-sided Colorectal Cancer\nEstimated prima
 ry completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06662786
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595874-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07595874)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant
  Botensilimab and Balstilimab for the Treatment of Advanced Resectable Col
 orectal Cancer NEST3\nEstimated primary completion: 16 December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/botensilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07595874
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01174121-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01174121)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients Wit
 h Metastatic Cancer\nEstimated primary completion: 27 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT01174121
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284849-2547@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:INCA33890: Phase 3 readout est. (NCT07284849)
DESCRIPTION:INCA33890\, phase 3\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevaciz
 umab With or Without INCA33890 in the First-Line Treatment of Metastatic M
 icrosatellite Stable Colorectal Cancer\nEstimated primary completion: 29 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inca338
 90#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7284849
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980532-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT06980
 532)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: Glumetinib Combined With Fruquintinib in the Treatment of MET 
 Amplification or Protein Overexpression in Third-Line Unresectable Metasta
 tic Colorectal Cancer\nEstimated primary completion: 30 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06980532
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729605-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07729605)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFIRI Plus
  Bevacizuamb and QL1706 in Second-Line Treatment for mCRC\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07729605
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362836-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0736283
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line
  RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)\nEstimated primary comp
 letion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07362836
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616183-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT04616183)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: L
 Y3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Tr
 eatment of Unresectable or Metastatic Colorectal Cancer\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04616183
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391566-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07391566)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: LPM6690176
  in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal
  Cancer Patients With RAS Mutation\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 91566
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944237-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05944237)
DESCRIPTION:Atezolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: HTL003973
 2 in Participants With Advanced Solid Tumours\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05944237
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446387-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07446387)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: A Clinical Study of Iparomlimab and Tuvonralimab Combined 
 With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-
 line Treatment for Unresectable Advanced Colorectal Cancer\nEstimated prim
 ary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07446387
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502014-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07502014)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: A Clinical Study of Iparomlimab and Tuvonralimab Combined 
 With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Th
 ird-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer\nE
 stimated primary completion: 31 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07502014
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631884-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07631884)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetec
 an in the Treatment of HER2-Expressiong Advanced Solid Tumor\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07631884
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Beamion B
 CGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Co
 mbination With Other Treatments to Test Whether it Helps People With Diffe
 rent Types of HER2+ Cancer That Has Spread\nEstimated primary completion: 
 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06324357
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900165-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07900165)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of V
 arsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorecta
 l Cancer\nEstimated primary completion: February 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900165
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395063-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07395063)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Clinical S
 tudy on the Treatment of Metastatic Colorectal Cancer at the Second-line o
 r Beyond.\nEstimated primary completion: 1 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07395063
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395063-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07395063)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Clinical 
 Study on the Treatment of Metastatic Colorectal Cancer at the Second-line 
 or Beyond.\nEstimated primary completion: 1 February 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07395063
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797077-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05797077)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Postoperati
 on Maintenance Therapy for Resectable Liver Metastases of Colorectal Cance
 r Guided by ctDNA\nEstimated primary completion: 20 February 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05797077
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262619-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07262619)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: EIK1005-
 002: A Clinical Research Study Evaluating EIK1005\, a Werner Helicase Inhi
 bitor\, as Monotherapy and in Combination With Pembrolizumab in Participan
 ts With Advanced Solid Tumors Including Microsatellite Instability High (M
 SI-H) Tumors\nEstimated primary completion: March 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07262619
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412198-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06412198)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  Multicenter Phase 1b/2 Study of Adagrasib\, Cetuximab\, and Cemiplimab fo
 r Metastatic Colorectal Cancer Harboring KRAS G12C Mutations\nEstimated pr
 imary completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06412198
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797244-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07797244)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Single-Arm
 \, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevaci
 zumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Canc
 er With Liver Metastases (CRLM)\nEstimated primary completion: April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07797244
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207656-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06207656)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Study to Eva
 luate the Efficacy and Safety of Cetuximab in Combination with Encorafenib
  Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial
 ly Resectable or Potentially Resectable Advanced Colorectal Cancer\nEstima
 ted primary completion: 1 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06207656
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885384-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290428
DTEND;VALUE=DATE:20290429
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0788538
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: Fruquintinib Combined With Capecitabine as Adjuvant Extended The
 rapy After R0 Resection and Perioperative Chemotherapy in Patients With Li
 ver-Only Metastatic Colorectal Cancer\nEstimated primary completion: 28 Ap
 ril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 885384
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885384-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290428
DTEND;VALUE=DATE:20290429
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07885384)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Fruquintini
 b Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resecti
 on and Perioperative Chemotherapy in Patients With Liver-Only Metastatic C
 olorectal Cancer\nEstimated primary completion: 28 April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07885384
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525206-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07525206)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study to A
 ccess Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bev
 acizumab Compared to Standard of Care IV Bevacizumabin Combination With Or
 al Trifluridine and Tipiracil in Adult Participants With Refractory Metast
 atic Colorectal Cancer\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07525206
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525206-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07525206)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Colorectal Cancer.\nStudy:
  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combinatio
 n With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combin
 ation With Oral Trifluridine and Tipiracil in Adult Participants With Refr
 actory Metastatic Colorectal Cancer\nEstimated primary completion: May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adiz
 utecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07525206
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823322-2547@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:INCA33890: Phase 2 readout est. (NCT07823322)
DESCRIPTION:INCA33890\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage I
 I/III Microsatellite Stable Colorectal Cancer After Curative Resection and
  Chemotherapy\nEstimated primary completion: 14 May 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/inca33890#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07823322
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863869-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290527
DTEND;VALUE=DATE:20290528
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07863869)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: The QL1706
  Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potenti
 ally Resectable Colorectal Cancer Patients With Liver Metastases\nEstimate
 d primary completion: 27 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07863869
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728019-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07728019)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Efficacy and
  Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or With
 out Short-Course Radiotherapy in Patients With CRCLM\nEstimated primary co
 mpletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07728019
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359456-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07359456)
DESCRIPTION:Ivonescimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: T
 esting Ivonescimab in Combination With Chemotherapy in Patients With Metas
 tatic Colorectal Cancers Without Liver Metastases\nEstimated primary compl
 etion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 vonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07359456
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630624-2292@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:N-dihydrogalactochitosan: Phase 1/2 readout est. (NCT06630624)
DESCRIPTION:N-dihydrogalactochitosan\, phase 1/2\, Colorectal Cancer.\nStud
 y: Dose Finding\, Efficacy and Immunological Response of IP-001 Following 
 MWA or IRE for CRLM\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactochitosan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06630624
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551596-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290828
DTEND;VALUE=DATE:20290829
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07551596)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Testing the
  Combination of Anti-Cancer Drugs\, Botensilimab (AGEN1181) and Balstilima
 b (AGEN2034)\, After Standard Treatment for Colorectal Cancer\, Combat Tri
 al\nEstimated primary completion: 28 August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07551596
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04188145-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04188145)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Randomized
  Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + B
 evacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta
 static Colorectal Cancer\nEstimated primary completion: September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04188145
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Clinical S
 tudy of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus 
 Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer\nE
 stimated primary completion: September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Colorectal Cancer.\nStudy: A 
 Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizum
 ab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
  Cancer\nEstimated primary completion: September 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790510-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07790510)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: H
 SK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in
  BRAF V600-Mutant Metastatic Colorectal Cancer\nEstimated primary completi
 on: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07790510
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587128-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT04587128)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Ear
 ly-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients Wi
 th mCRC\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04587128
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587128-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04587128)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Early-Line A
 nti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC\n
 Estimated primary completion: October 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04587128
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770102-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05770102)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: DETERMINE
  Trial Treatment Arm 02: Atezolizumab in Adult\, Paediatric and Teenage/Yo
 ung Adult Patients With Cancers With High Tumour Mutational Burden (TMB) o
 r Microsatellite Instability-high (MSI-high) or Proven Constitutional Mism
 atch Repair Deficiency (CMMRD) Disposition\nEstimated primary completion: 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05770102
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinic
 al Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestin
 al Cancers (MK-9999-02A)\nEstimated primary completion: 16 October 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549412-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07549412)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of P
 recemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridin
 e/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metas
 tatic Colorectal Cancer (PROCEADE-CRC-03)\nEstimated primary completion: 1
 6 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07549412
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549412-2612@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:precemtabart tocentecan: Phase 3 readout est. (NCT07549412)
DESCRIPTION:precemtabart tocentecan\, phase 3\, Metastatic Colorectal Cance
 r.\nStudy: A Study of Precemtabart Tocentecan With or Without Bevacizumab 
 Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With P
 reviously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)\nEstimate
 d primary completion: 16 October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/precemtabart-tocentecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07549412
URL:https://assetmemo.bio/drug/precemtabart-tocentecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Ipilimumab\, phase 1/2\, Colorectal Cancer.\nStudy: Triplex Che
 ckpoint Inhibitors Therapy for Advanced Solid Tumors\nEstimated primary co
 mpletion: 30 October 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05187338
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683949-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07683949)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Clinical 
 Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients 
 With Advanced Colorectal Cancer Refractory to Irinotecan\, Oxaliplatin\, a
 nd Fluoropyrimidine\nEstimated primary completion: 31 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07683949
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023289-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07023289)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Assess Adverse Events and Change in Disease Activity in Adult 
 Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alon
 e or With Standard of Care in Participants With Post Adjuvant Circulating 
 Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disea
 se\nEstimated primary completion: November 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023289
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462613-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05462613)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Regorafeni
 b With Low-dose Chemotherapies and Aspirin Followed by Standard Chemothera
 pies in Metastatic Colorectal Cancer\nEstimated primary completion: Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0546
 2613
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462613-2058@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Regorafenib: Phase 2/3 readout est. (NCT05462613)
DESCRIPTION:Regorafenib\, phase 2/3\, Colorectal Cancer.\nStudy: Regorafeni
 b With Low-dose Chemotherapies and Aspirin Followed by Standard Chemothera
 pies in Metastatic Colorectal Cancer\nEstimated primary completion: Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0546
 2613
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197322-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05197322)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: NEOadjuvan
 t PembRolizumab In Stratified Medicine - ColoRectal Cancer\nEstimated prim
 ary completion: 1 November 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05197322
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621497-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07621497)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: FOL
 FOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresect
 able Metastatic Colorectal Cancer (Phase II)\nEstimated primary completion
 : 1 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07621497
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621497-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07621497)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFOX8 Vers
 us mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Meta
 static Colorectal Cancer (Phase II)\nEstimated primary completion: 1 Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 21497
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365592-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07365592)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Neoadjuva
 nt Chemotherapy\, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced 
 pMMR CRC\nEstimated primary completion: 1 December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07365592
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926477-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07926477)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Trastuzumab 
 Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With 
 HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation\nEs
 timated primary completion: 1 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07926477
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926477-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07926477)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: Tr
 astuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated 
 mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mu
 tation\nEstimated primary completion: 1 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07926477
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283367-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07283367)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer 
 Patients.\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07283367
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283367-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07283367)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase I
 b/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer
  Patients.\nEstimated primary completion: 31 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07283367
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286695-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0728669
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevaciz
 umab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorect
 al Cancer\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07286695
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789210-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Encorafenib: Phase 2 readout est. (NCT07789210)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: A Single-Arm
 \, Phase II\, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus C
 etuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mut
 ant Colorectal Cancer With or Without Resectable Metastases\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07789210
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856837-2237@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0685683
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With 
 Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pM
 MR) Metastatic Colorectal Cancer Without Active Liver Metastases\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06856837
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221357-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300202
DTEND;VALUE=DATE:20300203
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07221357)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemoth
 erapy Versus Bevacizumab in Combination With Chemotherapy in Participants 
 With Previously Untreated\, Unresectable\, or Metastatic Colorectal Cancer
 \nEstimated primary completion: 2 February 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07221357
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222800-1989@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300223
DTEND;VALUE=DATE:20300224
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222800)
DESCRIPTION:PF-08634404\, phase 3\, Colorectal Cancer.\nStudy: Symbiotic-GI
 -03: A Study to Learn About the Study Medicine Called PF-08634404 in Combi
 nation With Chemotherapy in Adult Participants With Metastatic Colorectal 
 Cancer\nEstimated primary completion: 23 February 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07222800
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797467-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05797467)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Adjuvant Che
 motherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal C
 ancer Patients\nEstimated primary completion: 1 April 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05797467
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07750158)
DESCRIPTION:Pembrolizumab\, phase 3\, Colorectal Cancer.\nStudy: Zanzalinti
 nib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa 
 in Participants With Colorectal Cancer With Molecular Residual Disease\nEs
 timated primary completion: 5 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-2259@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07750158)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Colorectal Cancer.\nStudy: Zanzalintinib Alone or in Combination With Pe
 mbrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Can
 cer With Molecular Residual Disease\nEstimated primary completion: 5 April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-
 berahyaluronidase-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-2819@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07750158)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Zanzalinti
 nib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa 
 in Participants With Colorectal Cancer With Molecular Residual Disease\nEs
 timated primary completion: 5 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Nivolumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long-Te
 rm Extension Study for Participants Previously Enrolled in an Exelixis-Spo
 nsored Study\nEstimated primary completion: 31 May 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2819@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Long-Term 
 Extension Study for Participants Previously Enrolled in an Exelixis-Sponso
 red Study\nEstimated primary completion: 31 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124884-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07124884)
DESCRIPTION:Sotorasib\, phase 2\, Colorectal Cancer.\nStudy: 5-fluorouracil
  Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First
 -line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherap
 y With Advanced Unresectab\nEstimated primary completion: 30 June 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07124884
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05131919-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05131919)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Pembrolizu
 mab for Locally Advanced\, Irresectable\, Non-metastatic dMMR Colorectal C
 ancers\nEstimated primary completion: July 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05131919
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281768-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07281768)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Capecitabin
 e/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REG
 N7075 in Locally Advanced Rectal Cancer\nEstimated primary completion: Jul
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 1768
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805551-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07805551)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  HDM2017 Combination Therapy in Advanced Colorectal Cancer\nEstimated prim
 ary completion: August 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07805551
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805551-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07805551)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study o
 f HDM2017 Combination Therapy in Advanced Colorectal Cancer\nEstimated pri
 mary completion: August 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07805551
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389265-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07389265)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: Con
 tinuation of Cetuximab Beyond First-Line Progression in Metastatic Colorec
 tal Cancer\nEstimated primary completion: October 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07389265
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227636-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07227636)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of 
 Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surge
 ry and Chemotherapy\nEstimated primary completion: November 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/botensilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227636
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2271@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Tucatinib\, phase 1/2\, Colorectal Cancer.\nStudy: PRE-ISPY Pha
 se I/II Oncology Platform Program\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058682
 26
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958419-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06958419)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Node-Spari
 ng Short-Course Radiotherapy Plus Chemotherapy\, Bevacizumab and PD-1 Inhi
 bitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)\nEstimated pri
 mary completion: 31 December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06958419
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791512-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06791512)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: mFOLFOX6 + B
 evacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMM
 R/MSS CRC\nEstimated primary completion: 31 December 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06791512
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585279-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07585279)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Clinical
  Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Color
 ectal Cancer\nEstimated primary completion: 28 February 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07585279
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271355-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07271355)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Pressurized 
 Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment 
 of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases\,
  The IMPACT Trial\nEstimated primary completion: 28 February 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07271355
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381764-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310330
DTEND;VALUE=DATE:20310331
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07381764)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: ROM
 ANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil
  Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"\nE
 stimated primary completion: 30 March 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07381764
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071714-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07071714)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II S
 tudy of SHR-8068 Injection in Combination With Anti-tumor Therapies in Col
 orectal Cancer\nEstimated primary completion: October 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07071714
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403877-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07403877)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant I
 mmunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Can
 cer\nEstimated primary completion: 31 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07403877
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340567-9047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07340567)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Personalizi
 ng Chemotherapy Selection After Surgery for Patients With Stage III Colore
 ctal Cancer Using a Blood Test\nEstimated primary completion: 1 November 2
 032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0734056
 7
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321847-2292@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:N-dihydrogalactochitosan: Phase 2/3 readout est. (NCT07321847)
DESCRIPTION:N-dihydrogalactochitosan\, phase 2/3\, Colorectal Cancer.\nStud
 y: Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients W
 ith Colorectal Liver Metastases\nEstimated primary completion: December 20
 33. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactoc
 hitosan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07321847
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-1965@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Stu
 dy to Investigate Outcome of Individualized Treatment in Patients With Met
 astatic Colorectal Cancer\nEstimated primary completion: 31 December 2038.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Study to I
 nvestigate Outcome of Individualized Treatment in Patients With Metastatic
  Colorectal Cancer\nEstimated primary completion: 31 December 2038. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2219@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Study to Inv
 estigate Outcome of Individualized Treatment in Patients With Metastatic C
 olorectal Cancer\nEstimated primary completion: 31 December 2038. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02487992-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20430731
DTEND;VALUE=DATE:20430801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT02487992)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: The Study of
  CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With A
 dvanced Colorectal Cancer\nEstimated primary completion: July 2043. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02487992
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02487992-2242@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20430731
DTEND;VALUE=DATE:20430801
SUMMARY:S-1: Phase 2 readout est. (NCT02487992)
DESCRIPTION:S-1\, phase 2\, Colorectal Cancer.\nStudy: The Study of CIK Plu
 s S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced 
 Colorectal Cancer\nEstimated primary completion: July 2043. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT02487992
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
